Table 3.
Multivariate analysis of CCOC protein clusters and other clinicopathological parameters.
| # of events/n | comparison | Hazard Ratio (95% CI) | LRT p-value | |
|---|---|---|---|---|
|
| ||||
| Overall survival | 34 / 80 | |||
| Cluster (reference: Metabolic) | F,C,N* | 3.02 (1.44–6.69)F | 0.0027 | |
| Cluster (reference: Coagulative) | M,F,N* | 0.46 (0.22–0.96)F | 0.0364 | |
| Age and diagnosis | 1.00 (0.96–1.04)F | 0.8952 | ||
| Stage (reference: Stage I) | II-IV | 7.98 (3.22–23.55)F | 0 | |
| Residual disease (reference: non-optimal) | optimal | 0.29 (0.14–0.61)F | 0.0015 | |
| ARID1A (IHC) (reference: 0) | 1/2 | 1.03 (0.49–2.26)F | 0.8882 | |
| Adjuvant treatment (reference: no) | yes | 0.06 (0.01–0.39)F | 0.013 | |
|
| ||||
| Progression-free survival | 37 / 78 | |||
| Cluster (reference: Metabolic) | F,C,N* | 3.02 (1.46–6.65)F | 0.002 | |
| Cluster (reference: Coagulative) | M,F,N* | 0.44 (0.21–0.92)F | 0.0274 | |
| Age and diagnosis | 0.98 (0.94–1.02)F | 0.3481 | ||
| Stage (reference: Stage I) | II-IV | 6.10 (2.79–14.80)F | 0 | |
| Residual disease (reference: non-optimal) | optimal | 0.24 (0.12–0.50)F | 0.0002 | |
| ARID1A (IHC) (reference: 0) | 1/2* | 1.07 (0.54–2.15)F | 0.8024 | |
| Adjuvant treatment (reference: no) | yes | 0.31 (0.06–3.09)F | 0.4782 | |
F
indicates that the Firth’s penalized maximum likelihood bias reduction method was used to estimate the hazard ratio.
*
Proteomic Cluster M: Metabolic active cluster; F: Fibrotic cluster; C: Coagulative cluster; N: Necrotic cluster